Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku to Codevelop Celltrion’s Rituxan Biosimilar
April 27, 2017
- Janssen Files Japan NDA for Multidrug-Resistant TB Drug
April 26, 2017
- Humira Filed for Pustular Psoriasis in Japan: AbbVie
April 26, 2017
- Mundipharma Japan Chief Voices Eagerness on Rare Cancer Therapies
April 25, 2017
- Kissei Ditches Dry Eye Med KCT-0809
April 25, 2017
- Lumicef PIII Kicks In for Axial Spondyloarthritis: Kyowa Kirin
April 25, 2017
- Drug Costs Can’t Be Curbed with Uniform Pricing of Gx, LLPs: Teva Takeda CEO
April 24, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies
April 24, 2017
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- Janssen Files Japan NDA for Psoriasis Med Guselkumab
April 21, 2017
- Lecture Materials Prepared from Information Taken from Medical Charts: Bayer’s Xarelto Issue Whistleblower
April 21, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
- Takeda’s “Health Innovation Park” Hoped to Bring Together Various Researchers, Other Companies Also Welcomed
April 20, 2017
- Eisai to Continue “Price Zero” Drug Supply to Stamp Out Lymphatic Filariasis
April 20, 2017
- Burosumab Hits Primary Endpoint in PIII for Adult X-Linked Hypophosphatemia: Kyowa Kirin
April 20, 2017
- “Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
April 20, 2017
- Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
- Japan Vaccine Files New Shingles Vaccine: GSK
April 19, 2017
- Biogen’s Sugino to Lead Amgen Astellas; R&D Head Torii Named Successor
April 19, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…